Research Article

Epigallocatechin-3-gallate confers protection against corticosterone-induced neuron injuries via restoring extracellular signal-regulated kinase 1/2 and phosphatidylinositol-3 kinase/protein kinase B signaling pathways

Xiaoling Zhao, Renjia Li, Hui Jin, Haimin Jin, Yonghui Wang, Wanqi Zhang, Haichao Wang, Weiqiang Chen

1 Tianjin Institute of Health and Environmental Medicine, Tianjin, China, 2 Tianjin Medical University, Tianjin, China, 3 Yan'an Hospital of Kunming City, Kunming, Yunnan province, China, 4 The Feinstein Institute for Medical Research, Manhasset, NY, United States of America, 5 Affiliated Hospital of Taishan Medical University, Taian, Shandong province, China, 6 Department of Emergency Medicine, North Shore University Hospital, Manhasset, NY, United States of America

☯ These authors contributed equally to this work.

* tjchenwq@sohu.com (WC); hwang@northwell.edu (HW)

Abstract

Extensive studies suggested epigallocatechin-3-gallate (EGCG) has significant neuroprotection against multiple central neural injuries, but the underlying mechanisms still remain poorly elucidated. Here we provide evidence to support the possible involvement of extracellular signal-regulated kinase 1/2 (ERK1/2) and phosphatidylinositol-3 kinase/protein kinase B (PI3K/AKT) pathways in EGCG-mediated protection against corticosterone-induced neuron injuries. As an essential stress hormone, corticosterone could induce obvious neurotoxicity in primary hippocampal neurons. Pre-treatment with EGCG ameliorated the corticosterone-induced decrease of ERK1/2 and PI3K/AKT phosphorylation, and attenuated the corticosterone-induced reduction of peroxisome proliferators-activated receptor-γ coactivator-1α (PGC-1α) expression and ATP production. Taken together, these findings indicated that EGCG has significant neuroprotection against corticosterone-induced neuron injuries partly via restoring the ERK1/2 and PI3K/AKT signaling pathways as well as the PGC-1α-mediated ATP production.

Introduction

As the most abundant polyphenol in green tea, epigallocatechin-3-gallate (EGCG) has been shown to exhibit beneficial effects against diverse central neural injuries, such as neurodegenerative diseases [1–3], stress-induced neural injuries [4, 5], cerebral ischemic injuries [6, 7],...
and the National Center of Complementary and Alternative Medicine (NCCAM, R01AT005076). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have declared that no competing interests exist.

**Abbreviations:** AKT, protein kinase B; AMPK, 5′-AMP-activated protein kinase; ATP, adenosine triphosphate; CORT, corticosterone; CREB, cAMP response element binding protein; EGCG, epigallocatechin-3-gallate; ERK1/2, extracellular signal-regulated kinase 1/2; GC, glucocorticoids; GTPs, green tea polyphenols; pAKT, phosphorylated protein kinase B; pERK1/2, phosphorylated extracellular signal-regulated kinase 1/2; PGC-1α, peroxisome proliferators-activated receptor-γ coactivator-1α; PI3K, phosphatidylinositol-3 kinase.

**Involvement of ERK1/2 and PI3K/AKT in EGCG-mediated neuroprotection**

EGCG (purity ≥ 99% by high-performance liquid chromatography) was provided by Hangzhou Hetian Biotech Co., Ltd (Hangzhou, Zhejiang Province, China). Neurobasal medium, Dulbecco’s modified eagle’s medium (DMEM), B27 supplement, and fetal bovine serum (FBS) were purchased from Invitrogen (Carlsbad, CA, USA). Corticosterone (CORT), trypsin, poly-L-lysine, hoechst33342, and 3-(4, 5-dimethyl thiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) were purchased from Sigma (St. Louis, MO, USA). LY294002 (an inhibitor of PI3K/AKT), U0126 (an inhibitor of MEK/ERK1/2), L-glutamate, and antibodies against ERK1, phospho-ERK1/2 (pERK1/2), AKT, phospho-AKT (Ser473), PGC-1α, and β-actin were purchased from Cell Signaling Technology (Danvers, MA, USA). ATP assay kit (ab83355) was purchased from Abcam (Cambridge, MA, USA). Ultrapure RNA kit was purchased from Beijing Kangwei Century Company (Beijing, China). All-in-one™ First Strand cDNA synthesis kit

**Materials and methods**

**Chemical and reagents**

EGCG and neuro-inflammation [8, 9], and neural injuries induced by toxic reagents [10]. EGCG is the main active component of green tea polyphenols (GTPs), accounting for 30–50% of the total catechins [11]. Due to the abundance of phenolic hydroxyl groups in its chemical structure, EGCG is generally considered as one of the most important naturally occurring anti-oxidant [12]. Besides its powerful anti-oxidative properties, EGCG also plays an important role in modulating metal-chelation [13], anti-apoptosis [14], mitochondrial-preservation [15], and cellular signal transductions [1, 14, 16]. At the present, there remains no effective medical treatment for neurodegenerative diseases and other central neural injuries [17]. Most of the commercial therapeutic agents are predominantly symptom-oriented and accompanied with lots of side effects [18]. Therefore it’s urgent and necessary to explore and develop some therapeutic agents with lower side effects and wider spectrum of targets to not only treat the symptoms but also potentially modulate the pathology of such diseases and dysfunctions. As EGCG possesses multifunctional bioactivities, more and more attentions are paid to extensively investigate EGCG as a good candidate for a potent disease-modifying agent with neuro-rescue and neuro-protective properties.

Despite recent progress, more efforts are still needed to elucidate the molecular mechanisms underlying EGCG-mediated neuroprotection. Studies suggested that EGCG interacts directly with some neurotransmitter receptors, downstream protein kinases and stress-sensitive signaling cascades such as protein kinase C (PKC), protein kinase B (PKB/AKT) and Mitogen-activated protein kinase (MAPK) signaling pathways, which further dictates the neuronal cellular response to stress, thereby affecting cell proliferation, apoptosis, synthesis of inflammatory mediators and neurite growth [19, 20]. Our latest study indicated that EGCG protects against stress-induced central neural injuries by enhancing extracellular signal-regulated kinase 1/2 (ERK1/2) and PKCα signaling [4]. To further determine EGCG’s prominent regulating properties on stress-induced cellular signaling alterations and identify the potential molecular targets of EGCG-mediated neuroprotection, we conducted the present study. As an essential stress hormone, corticosterone (CORT) exposure could cause significant cytotoxicity including DNA damage, differential protein activation and cell apoptosis [21, 22]. The molecular mechanisms underlying the CORT-induced neuronal injuries were partly dependent on the inhibition of ERK1/2 and phosphatidylinositol-3 kinase/protein kinase B (PI3K/AKT) pathways [23–25]. Therefore, in this study we employed corticosterone to induce neuronal stress in primary rat hippocampal neurons, and the modulating effects of EGCG on two stress-susceptible signaling pathways, namely ERK1/2 and PI3K/AKT pathways were examined in vitro to elucidate EGCG’s neuroprotective mechanisms.
was provided by Guangzhou GeneCopoeia Co., Ltd, (Guangzhou, China). Other chemicals and reagents were of the highest analytic grade and were purchased from Beijing Chemical Reagent Company (Beijing, China).

**Cell culture**

The newborn (postnatal day 1) Wistar rats were obtained from the Experimental Animal Center of the Academy of Military Medical Sciences. All experimental procedures were taken in accordance with Tianjin Institute of Health and Environmental Medicine experimental standards as well as international guidelines on the ethical treatment of laboratory animals. Primary hippocampal neuronal cultures were prepared as described previously [26] with some modifications. Briefly, after treatment with 0.125% trypsin for 15 min at 37°C in Ca\(^{2+}\) and Mg\(^{2+}\) free Hank’s balanced salt solution, the hippocampi were washed in DMEM with 10% FBS in order to stop trypsin activity. Then the cells were re-suspended in DMEM supplemented with 10% FBS and plated onto poly-L-lysine-coated plates for 24 h at 37°C in a humidified atmosphere of 95% air and 5% CO\(_2\). Following cellular attachment, the culture medium was replaced with neuronal culture medium, namely serum-free Neurobasal medium with 2% B27 supplement, 0.5 mM glutamine, 100 U/mL penicillin and 100 U/mL streptomycin, followed by re-incubation for 7–8 days, the time required for maturation of hippocampal neurons, with half of the medium being changed every 3 days. Then, the cells were characterized by immunocytochemistry for neurofilament protein and fibrillary acidic protein, revealing that the cell cultures contained about 98% neurons.

**Cell treatment**

EGCG at different concentrations (0.1, 1, 5, 10 μmol/L) was added to primary hippocampal neuron cultures respectively 1 h before exposure to 10 μmol/L CORT and allow to co-incubation for an additional 24 h at 37°C in a humidified incubator of 5% CO\(_2\), 95% air environment, followed by various assessments at desired time. The hippocampal neurons undergoing neither EGCG pretreatment nor CORT stimulation served as control.

To investigate the involvement of PI3K/AKT and ERK1/2 signaling in EGCG-mediated neuroprotective effects, specific inhibitors for PI3K/AKT (LY294002, 10 μmol/L) or MEK/ERK1/2 (U0126, 10 μmol/L) were added 30 min before CORT-treatment in the absence or presence of EGCG (0.1 μmol/L), and further incubated for 24 h.

**Cell viability measurement**

Neuronal cell viability was determined by MTT assay based on the cleavage of the yellow tetrazolium salt MTT to purple formazan by mitochondrial enzymes in metabolically active cells. In brief, hippocampal neurons were cultured in 96-well plate at a density of 5×10⁵ cells per well. After stimulation with CORT, the cells were further incubated with the neuronal culture medium for a certain time period, and then 10 μl MTT solution were added to each well, and incubated at 37°C for 4 h. Afterwards, 100 μl of 20% sodium dodecyl sulfide (SDS) was added to dissolve the resulting formazan. The absorbance (OD) values were measured by spectrophotometry at 570 nm with an EIX-800 Micro-ELISA reader (Bio-Tek Inc., Winooski, VT). The cell viability data were expressed as a percentage of control value.

**Hoechst staining**

The hippocampal neurons were fixed in 4.0% paraformaldehyde for 20 min and stained with 5μg/ml Hoechst 33342 dye at 37°C for 10 min, followed by observation under a DMR.
fluorescence microscope (Leica Microsystems, Wentzler, Germany) with fluorescence excitation at 340 nm and emission at 510 nm. In order to quantify the apoptotic process, cells with fragmented or condensed DNA and normal DNA were respectively counted to calculate the ratio of apoptotic cells to total cells.

**Western blot analysis**

The cultured hippocampal neurons were subjected to western blot analysis for determining some proteins’ levels as per routine procedures. Briefly, cells were harvested and lysed in a lysis buffer. Protein concentrations were quantified using the BCA assay kit, followed by electrophoresis separation on 10% SDS-PAGE. After transferring to PVDF membranes, blocking with 20% bovine serum albumin (BSA) in Tris-buffered saline containing 0.05% Tween-20 (TBST) for 2 h at room temperature, the protein membranes were allowed to react with the respective primary monoclonal antibody overnight at 4°C. The primary antibodies and concentrations were ERK1/2 (1:1000); pERK1/2 (1:1000); AKT (1:1000); p-AKT (1:1000); PGC-1α (1:1500) and β-Actin (1:1000), respectively. β-actin was used as an internal loading control. Membranes were washed with TBST 5 times, and then probed with horseradish peroxidase (HRP)-conjugated secondary antibody (1:5000 dilutions in TBST) for 1 h at room temperature with gentle shaking. Membranes were washed with TBST, and the immuno-reactivity was detected with the Enhanced Chemiluminescence (ECL) Western Blot Detection system (WEST-ZOL® plus) and visualized with “ChemiDoc XRS” digital imaging system. Then protein expression was quantitated densitometrically with ’MultiAnalist’ software from Bio-Rad laboratories Inc.

**Detection of ATP contents in culture neurons**

The neuron cells of hippocampus were homogenized and ultra-sonicated for 1.5 min, and centrifuged at 15,000 g at 4°C for 10 min. The supernatant was assayed for ATP productions by using an ATP Assay Kit according to the manufacturer’s instructions.

**Real-time RT-PCR**

Total RNA was isolated from the primary cultured hippocampal neurons using the Ultrapure RNA Kit according to the manufacturer’s instructions, and its purity was confirmed by the A260/A280 ratio. Then the mRNA was reversely transcribed into the first-strand cDNA using All-in-one™ First Strand cDNA synthesis Kit. Following reverse transcription, All-in-one qPCR Primer (2 μM) and primers for glyceraldehyde 3-phosphate dehydrogenase gene (Gapdh; Qiagen, QT01658692) were used to quantify the mRNA expression levels of respective genes using an ABI 7300HT Real-time PCR system (Applied Bio-systems, Foster City, CA, USA). Amplification was performed using the RT² SYBR Green ROX qPCR Mastermix under the following conditions: 95°C 10 m; followed by 40 cycles of 95°C for 10 s, 60°C for 20 s and 72°C for 15 s. Immediately following the amplification step, a single cycle of the dissociation (melting) curve program was run at 95°C for 15 s, at 60°C for 20 s, then at 95°C for 15 s, and last at 60°C for 15 s. This cycle was followed by a melting curve analysis; baseline and cycle threshold values (Ct values) were automatically determined using the ABI 7300HT software. The relative mRNA expressions were calculated using the following formula: ΔΔC expression = 2−ΔΔCt, where ΔΔCt = ΔCt (modulated group)− ΔCt (control group), ΔCt = Ct (target gene)−Ct (GAPDH) and Ct = cycle at which the threshold was reached. The relative abundance of mRNA expression in normal control group was set as an arbitrary unit of 1, and the gene expression in modulated groups was presented as folds of controls after normalization to GAPDH.
Statistical analysis

The statistical analysis was performed using SPSS 10.0 software, and the results were expressed as mean ± SD (standard deviation). Experimental data were checked for Gaussian distribution. Two-tailed unpaired Student t tests were applied for comparison of two normally distributed groups; comparisons between more than two normally distributed groups were made by one-way ANOVA followed by pairwise multiple comparison (Student-Newman-Keuls method, q-test). Difference was considered statistically significant at $P<0.05$.

Results

Establishment of neuron stress model and EGCG’s protection in vitro

After treatment with CORT for 24 h, the hippocampal neurons demonstrated significant decrease of cell viability in 10 μmol/L and 100 μmol/L CORT treated groups (Fig 1A). At the concentration of 10 μmol/L, CORT treatment resulted in a decrease of relative cell viability to 56.3±10.8% in cultured hippocampal neurons. Thus, this concentration of CORT was used to induce neuron injuries in the subsequent experiments. When normal neurons were treated with EGCG for 24 h at different concentrations, there were no significant changes in cell viability if EGCG was given at concentrations < 100 μmol/L, indicating that EGCG itself exerts no toxicity on hippocampal neurons when given at reasonable doses (Fig 1B). Furthermore, EGCG evidently attenuated the CORT-induced decrease of cell viability in a dose-dependent manner between 0.1 and 5 μmol/L concentration while it remained ineffective at 10 μmol/L level (Fig 1C). As predicted, at extremely high concentration (100 μmol/L), EGCG itself caused a decrease of cell viability (Fig 1B).

In addition, the CORT-treated neurons displayed a significant morphological change, such as the disappearance of neurite, emergence of vacuoles around the cell body and decrease of cellular refraction (Fig 2B), while co-incubation with EGCG markedly attenuated these CORT-induced morphological changes (Fig 2C).

The effects of ERK1/2 and PI3K/AKT inhibition on EGCG-mediated neuroprotection

To elucidate the molecular mechanisms underlying EGCG-mediated neuroprotection, we determined the involvement of several signaling molecules using specific pharmacological
inhibitors. The co-incubation with inhibitors specific for ERK1/2 (U0126) or PI3K/AKT (LY294002) signaling pathways markedly abolished EGCG-mediated neuroprotective effects, as the cell viability remarkably declined compared with that of normal control group or EGCG/CORT-treated group (Table 1). By itself, U0126 or LY294002 did not affect cell viability in the primary hippocampal neurons in the absence of CORT or EGCG. The results of Hoechst 33342 staining of hippocampal neurons showed that EGCG improved the neuron injuries induced by CORT, such as nuclear shrinkage, pyknosis fragmentation and appearance of apoptotic bodies (Fig 3C). However, EGCG’s protective effects were impaired by co-incubation with U0126 or LY294002 (Fig 3D and 3E), as judged by the number of apoptotic bodies or calculated apoptotic index (Fig 3F).

CORT induces dynamic activation of ERK1/2 signaling pathway in primary hippocampal neuron cultures

Following stimulation with CORT (10 μmol/L) for different time period, the levels of phosphorylated ERK1/2 in primary hippocampal neuron cultures were altered in a time-dependent

Table 1. The effects of U0126 and LY294002 on EGCG-mediated neuroprotection against corticosterone-induced cell death (mean ± standard deviation).

| Group                        | Cell viability (%) |
|------------------------------|-------------------|
| Normal control               | 100               |
| CORT (10 μmol/L)             | 69.39 ± 7.63*     |
| U0126 alone (10 μmol/L)      | 98.54 ± 7.27      |
| LY294002 alone (10 μmol/L)   | 97.79 ± 8.76      |
| CORT (10 μmol/L) + EGCG (1 μmol/L) | 90.22 ± 9.41b |
| CORT (10 μmol/L) + EGCG (1 μmol/L) + U0126 (10 μmol/L) | 62.54 ± 10.22bc |
| CORT (10 μmol/L) + EGCG (1 μmol/L) + LY294002 (10 μmol/L) | 66.90 ± 3.78bc |

Primary hippocampal neuron cultures were treated with CORT for 24 h in the absence or presence of EGCG (1 μmol/L) pre-treatment (2 h prior to CORT stimulation), ERK1/2 inhibitor (U0126, 10 μmol/L) or PI3K/AKT inhibitor (LY294002, 10 μmol/L) pre-treatment (30 min before CORT exposure).

* P<0.05 vs Normal control group
b P<0.05 vs CORT group
bc P<0.05 vs CORT + EGCG group
fashion, first reduced between 1–2 h, but subsequently elevated between 12–24 h (Fig 4). The co-incubation with EGCG obviously prevented the CORT-induced early inhibition of ERK1/2 phosphorylation in a dose-dependent manner (Fig 5A, 5B and 5C). Furthermore, the ERK1/2 phosphorylation levels in EGCG treatment neurons were enhanced significantly compared with that of normal control neurons (Fig 5A, 5B and 5C). In a sharp contrast, EGCG did not affect the CORT-induced elevation of ERK1/2 phosphorylation at a later time point (e.g., 24 h post CORT stimulation) (Fig 5D, 5E and 5F).

CORT reduces PI3K/AKT phosphorylation in primary hippocampal neuron cultures

When the primary hippocampal neurons were treated with corticosterone, the level of phosphorylated PI3K/AKT was significantly decreased (Fig 6A and 6C). However, pre-treatment with EGCG significantly prevented the CORT-induced decrease of PI3K/AKT phosphorylation between 0.1 and 5 μmol/L concentration while had no effect at 10 μmol/L level (Fig 6B and 6D).
The expression of ERK1/2 and AKT mRNA in primary hippocampal neuron cultures

The expression of ERK1/2 and AKT mRNA in primary hippocampal neuron cultures were measured by RT-PCR. As shown in Fig 7, corticosterone and/or EGCG treatment at various doses did not alter the expression of ERK1/2 mRNA in the primary hippocampal neurons.
(Fig 7A). In contrast, corticosterone stimulation resulted in a significant reduction of AKT mRNA expression, but was dose-dependently attenuated by EGCG at concentrations between 0.1 and 5 μmol/L (Fig 7B). These changes of AKT mRNA were consistent with the aforementioned alteration of AKT phosphorylation following similar stimulation with EGCG and CORT.

The changes of ATP production and PGC-1α expressions in primary hippocampal neuron cultures

Compared with normal control group, corticosterone stimulation resulted in a reduction of ATP production in primary hippocampal neurons (Fig 8A), which was dose-dependently attenuated by EGCG pretreatment (Fig 8A). Western blot analysis revealed a time-dependent decrease in the expression of PGC-1α in the primary hippocampal neurons following stimulation with corticosterone (Fig 8B and 8E), which was similarly attenuated by EGCG pre-treatment in a dose-dependent fashion (Fig 8C and 8F). Consistently, EGCG pretreatment similarly prevented CORT-induced down-regulation of PGC-1α mRNA in primary hippocampal neurons (Fig 8D).
Discussion

In recent years, the ever-increasing psychological stress intensity and duration have brought about multiple stress-induced neural injuries which can dampen the risk of many neuropsychiatric disorders [27, 28]. Currently there are no effective strategies to prevent and treat such...
stress-induced neural injuries. Being endowed with various profitable properties, EGCG has been shown to possess powerful neuro-protective and neuro-rescue activities, which meets the demand for effective treatment for central neural dysfunctions. Before the potential therapeutic usage of EGCG clinically, more efforts should be made to elucidate the intricate mechanisms underlying the EGCG-mediated neuroprotection. In the present study, we provided evidence to support the notion that EGCG could protect against corticosterone-induced neural injuries in primary hippocampal neurons via restoring ERK1/2 and PI3K/AKT signaling pathways, as well as recovering the PGC-1α-mediated energy metabolism.

It is well-known that endogenic glucocorticoids (GCs) occupy an important role in the pathological impairments induced by stress and other insults [29, 30]. When exposed to psychogenic (e.g., fear or anxiety) or physical (e.g., cold, pathogen invasion or cellular lesion) stressors, the hypothalamic-pituitary-adrenal (HPA) axis is activated, resulting in the increased release of GCs to mount a critical physiological response to stress [31–33]. While GCs primarily act to maintain homeostasis by inducing physiological and behavioral adaptation, prolonged exposure to stress and elevated GCs levels may result in neuro- and psychopathology. Substantial experimental evidence has suggested that excessively elevated GCs levels and prolonged exposure to stressful conditions increase the susceptibility to develop behavioral impairments [4,5,34], metabolic, neuropsychiatric, and neurodegenerative disorders [35–37]. Furthermore, it also induces structural remodeling of neurons with synaptic loss as well as alterations in glial functions, which are frequently maladaptive [38]. As the prominent part of the limbic system in the central nervous system, hippocampus plays a critical role in mediating behavioral, functional and neuroendocrine responses to stress [39]. Carrying abundant receptors for stress hormones, the hippocampus is also the main cerebral domain to mediate stress response, as well as the primary target affected by the release of stress hormones [40]. Therefore, hippocampus is highly sensitive to stress and vulnerable to the subsequent release of glucocorticoids. In the present study, we used corticosterone to develop a cell model of stress in the primary cultured hippocampal neurons, and confirmed that corticosterone induced obvious neural injuries in a dose-dependent manner in rat hippocampal neurons.

Meanwhile, substantial evidence has supported an association between EGCG’s capacity in modulating various signaling pathways and its substantial neuro-protective/neuro-restorative effects. For instance, we recently reported that the PKCα and ERK1/2 signaling pathways are involved in EGCG’s protection against stress-induced neural injuries in vivo [4]. In the present study, we sought to further evaluate EGCG’s impact on these signaling pathways using an in vitro cellular model of neuronal injury induced by excessive corticosterone exposure. Our results demonstrated that EGCG dose-dependently attenuated the corticosterone-induced neuron injuries, but the EGCG-mediated neuroprotective effects were impaired by the pharmacological inhibition of the ERK1/2 and PI3K/AKT signaling pathways. Mechanistically, EGCG pre-treatment significantly attenuated the corticosterone-mediated inhibition of ERK1/2 and PI3K/AKT phosphorylation, which are critical merging points for many signaling cascades involved in the regulation of cell survival, cell growth and proliferation under physiological and pathophysiologic conditions [41, 42]. EGCG has been shown to modulate ERK and PI3K/AKT signaling systems in different tissues and cell lines [1, 4, 43–45]. In the nervous system, a low level of ERK activation is needed to promote neuronal growth, thereby facilitating neuronal plasticity and survival [46]. However, the excessive or extremely prolonged activation of the ERK pathway can be deleterious, and contributes to the pathogenesis of various neurodegenerative disorders such as Parkinson’s and Alzheimer’s diseases [47–49]. The present study also showed that pretreatment with EGCG for 1 h could prevent the CORT-induced early inhibition of ERK1/2 in hippocampal neurons. While EGCG treatment could not affect CORT-induced ERK1/2 activation at a later time point (e.g., 24 h post CORT stimulation),
which may contribute to the subsequent neuron injuries. In addition, our results showed that EGCG intervention significantly prevented corticosterone-induced decrease of AKT activation in hippocampal neurons. In response to a variety of extracellular factors (such as neurotropic factors, cytokines, hormones, neurotransmitters), PI3K is activated and further induces the phosphorylation of the serine–threonine kinase AKT, resulting in neuron proliferation, survival and differentiation [50, 51]. Multiple studies have demonstrated that EGCG could activate the PI3K/AKT signaling to improve learning and memory retention, inhibit sevoflurane-induced neurodegeneration [52], modulate neurogenesis and stroke recovery [53, 54], and promote cell growth and neuron differentiation [55]. Conceptually, the ERK1/2 and PI3K/AKT represent two independent parallel signaling pathways, which may cross-talk to regulate each other positively or negatively [56–59]. In differentiated human skeletal muscle cells, extracellular ATP could activate ERK1/2 phosphorylation which was strictly dependent on PI3K activity [60]. During brain ischemia/reperfusion, negative crosstalk exists between MAPK/ERK1/2 and PI3K/AKT pathways, which may be pharmacologically modulated for reducing neuronal injury [58]. Furthermore, once activated, ERK, AKT and other related kinases often act on common substrates, sometimes in concert to improve cell metabolism, proliferation, survival and motility [61, 62]. Collectively, the evidence strongly supports the notion that the activation of ERK1/2 and PI3K/AKT signaling pathways underlies the EGCG-mediated neuroprotective effects. In the future, more work is required to fully understand the specific interaction between MAPK/ERK and PI3K/AKT pathways, including the extent of their crosstalk and its significance in EGCG-mediated therapeutic potential in central neural injuries.

As a higher energy demanding system, the cerebrum is particularly vulnerable to dysfunctional energy metabolism, which impairs the nervous system development and contributes to the pathogenesis of various neurodevelopmental disorders [63–66]. We have recently demonstrated that the ATP production and the expression of a key energy modulator, PGC-1α, were significantly declined in the hippocampus and neocortex of stress animals [4]. In the present study, we further showed that ATP content and PGC-1α expression were both decreased in the corticosterone-stimulated hippocampal neurons, which was similarly attenuated by EGCG pretreatment. In agreement with the essential role of PGC-1α in the regulation of mitochondrial oxidative metabolism, respiration and mitochondrial biogenesis [67,68], our findings suggested that EGCG’s neuroprotection may be partly associated with its enhancement of PGC-1α expressions as well as the resultant ATP production in hippocampal neurons. In other neuronal cells (e.g., PC12), EGCG could suppress the 1-methyl-4-phenyl-pyridine (MPP)-induced oxidative stress by upregulating PGC-1α mRNA levels [69]. In hippocampal progenitor cells from a Down syndrome mouse model and cells derived from patients with Down’s syndrome, EGCG could also sustain and enhance mitochondrial functions by up-regulating PGC-1α/SIRT1/AMPK axis as well as increasing SIRT1-dependent PGC-1α deacetylation [64, 66]. In addition, the most recent studies suggested that PGC-1α could interact or collaborate with critical cellular signaling pathways, such as NF-κB [70], ERK1/2 [71], PI3K/AKT [72, 73], cAMP response element binding protein (CREB) [74] and AMPK [75] pathways, and collectively modulate mitochondrial functions in physiological and pathological conditions. So the modulation of intracellular pathways by EGCG, which ultimately restore mitochondrial functions, could explain, at least partly, the effects of such natural active substances in ameliorating the stress- or corticosterone- induced neural injuries.

In summary, the present report suggests that EGCG exerts neuro-protection against the corticosterone-induced neuron injuries via restoration of ERK1/2 and PI3K/AKT signaling pathways, and promotion of PGC-1α expressions as well as ATP production in the primary hippocampal neurons. This further verified the intricate molecular mechanisms underlying
EGCG-mediated neuro-protection against stress/stress hormone-induced neural injuries. This research paves the way for using natural active substances as a potential therapeutic tool in preventing or managing stress-related and other diverse neural dysfunctions.

Acknowledgments

This work was supported by the National Nature Science Foundation of China (NSFC, No. 81372987 and No. 81072294 to W.C.). H.W. was supported by the National Institute of General Medical Sciences (NIGMS, R01GM063075 and 1R41GM123858) and the National Center of Complementary and Alternative Medicine (NCCAM, R01AT005076).

Author Contributions

Conceptualization: Weiqiang Chen.

Data curation: Xiaoling Zhao, Hui Jin, Haichao Wang.

Formal analysis: Xiaoling Zhao, Weiqiang Chen.

Funding acquisition: Weiqiang Chen.

Investigation: Xiaoling Zhao, Renjia Li, Haimin Jin, Yonghui Wang, Weiqiang Chen.

Methodology: Xiaoling Zhao, Renjia Li, Haimin Jin, Yonghui Wang.

Writing – original draft: Hui Jin, Weiqiang Chen.

Writing – review & editing: Wanqi Zhang, Haichao Wang.

References

1. Yamamoto N, Shibata M, Ishikuro R, Tanida M, Taniguchi Y, Ikeda-Matsuo Y, et al. Epigallocatechin gallate induces extracellular degradation of amyloid β-protein by increasing nephrilysin secretion from astrocytes through activation of ERK and PI3K pathways. Neuroscience. 2017; 362:70–78. https://doi.org/10.1016/j.neuroscience.2017.08.030 PMID: 28844000

2. Xicota L, Rodríguez-Morato J, Dierssen M, de la Torre R. Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease. Curr Drug Targets. 2017; 18:174–195. https://doi.org/10.2174/13894501166661666150825113655 PMID: 26302801

3. Gu H, Nie Y, Tong Q, Tang Y, Zeng Y, Jing K, et al. Epigallocatechin-3-Gallate Attenuates Impairment of Learning and Memory in Chronic Unpredictable Mild Stress-Treated Rats by Restoring Hippocampal Autophagic Flux. PLoS One. 2014; 9:e112683. https://doi.org/10.1371/journal.pone.0112683 PMID: 25393306

4. Zhao X, Liu F, Jin H, Li R, Wang Y, Zhang W, et al. Involvement of PKCα and ERK1/2 signaling pathways in EGCG’s protection against stress-induced neural injuries in Wistar rats. Neuroscience. 2017; 346:226–237. https://doi.org/10.1016/j.neuroscience.2017.01.025 PMID: 28131624

5. Chen WQ, Zhao XL, Wang DL, Li ST, Hou Y, Hong Y, et al. Effects of epigallocatechin-3-gallate on behavioral impairments induced by psychological stress in rats. Exp Bio Med. 2010; 235: 577–583.

6. Han J, Wang M, Jing X, Shi H, Ren M, Lou H. (-)-Epigallocatechin gallate protects against cerebral ischemia-induced oxidative stress via Nrf2/ARE signaling. Neurochem Res. 2014; 39:1292–1299. https://doi.org/10.1007/s11064-014-1311-5 PMID: 24792731

7. Yao C, Zhang J, Liu G, Chen F, Lin Y. Neuroprotection by (-)-epigallocatechin-3-gallate in a rat model of stroke is mediated through inhibition of endoplasmic reticulum stress. Mol Med Rep. 2014; 9:69–76. https://doi.org/10.3892/mmr.2013.1778 PMID: 24193141

8. Liu JB, Zhou L, Wang YZ, Wang X, Zhou Y, Ho WZ, et al. Neuroprotective Activity of (-)-Epigallocatechin Gallate against Lippopolysaccharide-Mediated Cytotoxicity. J Immunol. 2016; 2016:4962351. https://doi.org/10.1155/2016/4962351 PMID: 27191001

9. Seong KJ, Lee HG, Kook MS, Ko HM, Jung JY, Kim WJ. Epigallocatechin-3-gallate rescues LPS-impaired adult hippocampal neurogenesis through suppressing the TLR4-NF-κB signaling pathway in mice. Korean J Physiol Pharmacol. 2016; 20:41–51. https://doi.org/10.4196/kjpp.2016.20.1.41 PMID: 26807022
10. Chen D, Kanthasamy AG, Reddy MB. EGCG Protects against 6-OHDA-induced neurotoxicity in a cell culture model. Parkinsons Dis. 2015; 2015:843906. https://doi.org/10.1155/2015/843906 PMID: 26770869

11. Yang CS, Lambert JD, Ju J, Lu G and Sang S. Tea and cancer prevention: molecular mechanisms and human relevance. Toxicol Appl Pharmacol. 2007; 224: 265–273. https://doi.org/10.1016/j.taap.2006.11.024 PMID: 17234229

12. Ou HC, Song TY, Yeh YC, Huang CY, Yang SF, Chiu TH, et al. EGCG protects against oxidized LDL-induced endothelial dysfunction by inhibiting LOX-1-mediated signaling. J Appl Physiol. 2010; 108:1745–1756. https://doi.org/10.1152/japplphysiol.00879.2009 PMID: 20203069

13. Zhang B, Russiano D and Osborne NN. Orally administered epigallocatechin gallate attenuates retinal neuronal death in vivo and light-induced apoptosis in vitro. Brain Res. 2008; 1198:141–152. https://doi.org/10.1016/j.brainres.2007.11.071 PMID: 18255049

14. Liu S, Sun Z, Chu P, Li H, Ahsan A, Zhou Z, et al. EGCG protects against homocysteine-induced human umbilical vein endothelial cells apoptosis by modulating mitochondrial-dependent apoptotic signaling and PI3K/Akt/eNOS signaling pathways. Apoptosis. 2017; 22:672–680. https://doi.org/10.1007/s10495-017-1360-8 PMID: 28317089

15. Sutherland BA, Shaw OM, Clarkson AN, Jackson DM, Sammut IA and Appleton I. Neuroprotective effects of (-)-epigallocatechin gallate after hypoxia-ischemia-induced brain damage: novel mechanisms of action. FASEB J. 2005; 19:258–260. https://doi.org/10.1096/fj.04-28065 PMID: 15569775

16. Shen X, Zhang Y, Feng Y, Zhang L, Li J, Xie YA, et al. Epigallocatechin-3-gallate inhibits cell growth, induces apoptosis and causes S phase arrest in hepatocellular carcinoma by suppressing the AKT pathway. Int J Oncol. 2014; 44:791–796. https://doi.org/10.3892/ijo.2014.2251 PMID: 24402647

17. Singh NA, Mandal AK, Khan ZA. Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG). Nutr J. 2016; 15:60. https://doi.org/10.1186/s12937-016-0179-4 PMID: 27268025

18. Huang Y and Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012; 148:1204–1222. https://doi.org/10.1016/j.cell.2012.02.040 PMID: 22424330

19. Menard C, Bastianetto S, Quirion R. Neuroprotective effects of resveratrol and epigallocatechin gallate polyphenols are mediated by the activation of protein kinase C gamma. Front Cell Neurosci. 2013; 7:281. https://doi.org/10.3389/fncel.2013.00281 PMID: 24421757

20. Kennedy DO. Polyphenols and the human brain: plant "secondary metabolite" ecologic roles and endogenous signaling functions drive benefits. Adv Nutr. 2014; 5:515–533. https://doi.org/10.3945/an.114.006320 PMID: 25469384

21. Zhu MY, Wang WP, Bissette G. Neuroprotective effects of agmatine against cell damage caused by glucocorticoids in cultured rat hippocampal neurons. Neuroscience. 2006; 141: 2019–2027. https://doi.org/10.1016/j.neuroscience.2005.05.011 PMID: 16777341

22. Zheng M, Liu C, Pan F, Shi D, Ma F, Zhang Y, et al. Protective effects of flavonoid extract from Apocynum venetum leaves against corticosterone induced neurotoxicity in PC12 cells. Cell Mol Neurobiol. 2011; 31: 421–428. https://doi.org/10.1007/s10571-010-9635-4 PMID: 21170580

23. Liu B, Zhang H, Xu C, Yang G, Tao J, Huang J, et al. Neuroprotective effects of icariin on corticosterone-induced apoptosis in primary cultured rat hippocampal neurons. Brain Res. 2011; 1375: 59–67. https://doi.org/10.1016/j.brainres.2012.02.053 PMID: 21182828

24. Zhang H, Liu B, Wu J, Xu C, Tao J, Duan X, et al. Icariin inhibits corticosterone-induced apoptosis in hypothalamic neurons via the PI3-K/Akt signaling pathway. Mol Med Rep. 2012; 6: 967–972. https://doi.org/10.3892/mmr.2012.1041 PMID: 22930911

25. Howell KR, Kutiyawanawala A, Pillai A. Long-term continuous corticosterone treatment decreases VEGF receptor-2 expression in frontal cortex. PLoS One. 2011; 6:e20198. https://doi.org/10.1371/journal.pone.0020198 PMID: 21647420

26. Banker GA and Cowan WM. Rat hippocampal neurons in dispersed cell culture. Brain Res. 1977; 126:397–425. PMID: 861729

27. Franklin TB, Saab BJ and Mansuy IM. Neural mechanisms of stress resilience and vulnerability. Neuron. 2012; 75: 747–761. https://doi.org/10.1016/j.neuron.2012.08.016 PMID: 22958817

28. McEwen BS. Central effects of stress hormones in health and disease: understanding the protective and damaging effects of stress and stress mediators. Eur J Pharmacol. 2008; 583:174–185. https://doi.org/10.1016/j.ejphar.2007.11.071 PMID: 18282566

29. Bratt AM, Kelly SP, Knowles JP, Barrett J, Davis K, Davis M, et al. Long term modulation of the HPA axis by the hippocampus behavioral, biochemical and immunological endpoints in rats exposed to chronic mild stress. Psychoneuroendocrinol. 2001; 26:121–145.

30. Angelucci L. The glucocorticoid hormone: from pedestal to dust and back. Euro J Pharmcol. 2000; 405:139–147.
31. McCarty R. Learning about stress: neural, endocrine and behavioral adaptations. Stress. 2016; 19:449–475. https://doi.org/10.1080/10253890.2016.1192120 PMID: 27294884
32. Ulrich-Lai YM, Herman JP. Neural regulation of endocrine and autonomic stress responses. Nature Rev Neurosci. 2009; 10:397–409.
33. Vyas S, Rodrigues AJ, Silva JM, Tronche F, Almeida OF, Sousa N, et al. Chronic Stress and Glucocorticoids: From Neuronal Plasticity to Neurodegeneration. Neural Plast. 2016; 2016:6391686. https://doi.org/10.1155/2016/6391686 PMID: 27034847
34. Chen WQ, Zhao XL, Hou Y, Li ST, Hong Y, Wang DL, et al. Protective effects of green tea polyphenols on cognitive impairments induced by psychological stress in rats. Behav Brain Res. 2009; 202: 71–76. https://doi.org/10.1016/j.bbr.2009.03.017 PMID: 19447283
35. Chen Y and Baram TZ. Toward understanding how early life stress reprograms cognitive and emotional brain networks. Neuropsychopharmacology. 2016; 41: 197–206. https://doi.org/10.1038/npp.2015.181 PMID: 26105143
36. Harris A and Seckl J. Glucocorticoids, prenatal stress and the programming of disease. Horm Behav. 2011; 59: 279–289. https://doi.org/10.1016/j.yhbeh.2010.06.007 PMID: 20591431
37. Moisidis VG and Matthews SG. Glucocorticoids and fetal programming part 1: outcomes. Nat Rev Endocrinol. 2014; 10: 391–402. https://doi.org/10.1038/nrendo.2014.73 PMID: 24683382
38. Sousa N and Almeida OFX. Disconnection and reconnection: the morphological basis of (mal)adaptation to stress. Trends Neurosci. 2012; 35:742–751. https://doi.org/10.1016/j.tins.2012.08.006 PMID: 23000140
39. de Kloet ER, Karst H, Joels M. Corticosteroid hormones in the central stress response: quick-and-slow. Front Neuroendocrinol. 2008; 29:268–272. https://doi.org/10.1016/j.yfne.2007.10.002 PMID: 18067954
40. Kondoh M, Inoue Y, Atagi S, Futakawa N, Higashimoto M and Sato M. Specific induction of metallothionein synthesis by mitochondrial oxidative stress. Life Sci. 2001; 69: 2137–2146. PMID: 11669457
41. Plotnikov A, Zehorai E, Procaccia S, Seger R. The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim Biophys Acta. 2011; 1813:1619–1633. https://doi.org/10.1016/j.bbamcr.2010.12.012 PMID: 21167873
42. Kyriakis JM and Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev. 2012; 92:689–737. https://doi.org/10.1152/physrev.00028.2011 PMID: 22535895
43. Liu S, Li H, Chen L, Yang L, Li L, Tao Y, et al. (–)-Epigallocatechin-3-gallate inhibition of Epstein-Barr virus spontaneous lytic infection involves ERK1/2 and PI3-K/Akt signaling in EBVpositive cells. Carcinogenesis. 2013; 34: 627–637. https://doi.org/10.1093/carcin/bg s364 PMID: 23180656
44. Xiao J, Ho CT. Liong E, Nanji AA, Leung TM, Lau TY, et al. Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways. Eur J Nutr. 2014; 53: 187–199. https://doi.org/10.1007/s00394-013-0516-8 PMID: 23515587
45. Satonaka H, Ishida K, Takai M, Koide R, Shigemasa R, Ueyama J, et al. (–)-Epigallocatechin-3-gallate Down-regulates Doxorubicin-induced Overexpression of P-glycoprotein Through the Coordinate Inhibition of PI3K/Akt and MEK/ERK Signaling Pathways. Anticancer Res. 2017; 37:6071–6077. https://doi.org/10.21873/anticancer.12055 PMID: 29061787
46. Cruz CD and Cruz F. The ERK 1 and 2 Pathway in the Nervous System: From Basic Aspects to Possible Clinical Applications in Pain and Visceral Dysfunction. Curr Neuropsychopharmacol. 2007; 5: 244–252. https://doi.org/10.2174/157015907782793630 PMID: 19305741
47. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD. Beta-amylloid activates the mitogen-activated protein kinase cascade hippocampal alpha7 nicotinic acetylcholine receptors: and mechanisms related to Alzheimer's disease. J Neurosci. 2001; 21: 4125–4133. PMID: 11404397
48. Kulich SM and Chu CT. Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease. J Neurochem. 2001; 77:1058–1066. PMID: 11359871
49. Russo C, Dolcini V, Salis S, Venezia V, Zambrano N, Russo T, et al. Signal transduction through tyrosine-phosphorylated C terminal fragments of amyloid precursor protein an enhanced interaction with Shc/Grb2 adaptor proteins in reactive astrocytes of Alzheimer's disease brain. J Biol Chem. 2002; 277:35282–35288. https://doi.org/10.1074/jbc.M110785200 PMID: 12084708
50. Hers I, Vincent EE, Tavare JM. Akt signalling in health and disease. Cell Signal. 2011; 23:1515–1527. https://doi.org/10.1016/j.cellsig.2011.05.004 PMID: 21620961
51. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 2005; 9:59–71. PMID: 15784165
52. Ding ML, Ma H, Man YG, Lv HY. Protective effects of a green tea polyphenol, epigallocatechin-3-gallate, against sevoflurane-induced neuronal apoptosis involve regulation of CREB/BDNF/TRKB and PI3K/Akt/mTOR signalling pathways in neonatal mice. Can J Physiol Pharmacol. 2017; 1–10. https://doi.org/10.1139/cjpp-2016-0333 PMID: 28679060

53. Ortiz-López L, Márquez-Valadez B, Gómez-Sánchez A, Silva-Lucero MD, Torres-Pérez M, Téllez-Ballesteros RI, et al. Green tea compound epigallocatechin-3-gallate (EGCG) increases neuronal survival in adult hippocampal neurogenesis in vivo and in vitro. Neuroscience. 2016; 322:208–220. https://doi.org/10.1016/j.neuroscience.2016.02.040 PMID: 26917271

54. Zhang JC, Xu H, Yuan Y, Chen JY, Zhang YJ, Lin Y, et al. Delayed Treatment with Green Tea Polyphenol EGCG Promotes Neurogenesis After Ischemic Stroke in Adult Mice. Mol Neurobiol. 2017; 54:3652–3664. https://doi.org/10.1007/s12035-016-9924-0 PMID: 27206430

55. Zhang Y, He Q, Dong J, Jia Z, Hao F, Shan C. Effects of epigallocatechin-3-gallate on proliferation and differentiation of mouse cochlear neural stem cells: Involvement of PI3K/Akt signaling pathway. Eur J Pharm Sci. 2016; 88:267–273. https://doi.org/10.1016/j.ejps.2016.03.017 PMID: 27012759

56. Hoeflich KP, O’Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, et al. In vivo antitumor activity of MEK inhibitors. Oncogene. 2010; 29:4135–4144. https://doi.org/10.1038/onc.2009.315 PMID: 20485732

57. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011; 36:320–328. https://doi.org/10.1016/j.tibs.2011.03.006 PMID: 21531565

58. Zhou J, Du T, Li B, Rong Y, Verkhovsky A, Peng L. Crosstalk between MAPK/ERK and PI3K/AKT signalling pathways during brain ischemia/reperfusion. ASN Neuro. 2015; 7(5). https://doi.org/10.1177/1759091415602463 PMID: 26428523

59. Carriere A, Romeo Y, Acosta-Jaquez HA, Moreau J, Bonneil E, Thibault P, et al. ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1). J Biol Chem. 2011; 286:567–577. https://doi.org/10.1074/jbc.M110.159046 PMID: 21071439

60. May C, Weigl L, Karel A, Hohenegger M. Extracellular ATP activates ERK1/ERK2 via a metabotropic P2Y1 receptor in a Ca2+ independent manner in differentiated human skeletal muscle cells. Biochem Pharmacol. 2006; 71:1497–509. https://doi.org/10.1016/j.bcp.2006.02.003 PMID: 16533496

61. Manning BD and Toker A. AKT/PKB Signaling: Navigating the Network. Cell. 2017; 169:381–405. https://doi.org/10.1016/j.cell.2017.04.017 PMID: 28431241

62. Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 2008; 10:138–148. https://doi.org/10.1038/ncb1676 PMID: 18204439

63. Wagatsuma A, Kotake N, Mabuchi K, Yamada S. Expression of nuclear-encoded genes involved in mitochondrial biogenesis and dynamics in experimentally denervated muscle. J Physiol Biochem. 2011; 67:359–370. https://doi.org/10.1083/jb.201003006 PMID: 19752021

64. Valenti D, de Bari L, de Rasmo D, Signorile A, Henrion-Cau de A, Contestabile A, et al. The polyphenols resveratrol and epigallocatechin-3-gallate restore the severe impairment of mitochondria in hippocampal progenitor cells from a Down syndrome mouse model. Biochim Biophys Acta. 2016; 1862:1093–1104. https://doi.org/10.1016/j.bbadis.2016.03.003 PMID: 26964795

65. Valenti D, de Bari L, de Filippis B, Henrion-Caud A, Vacca RA. Mitochondrial dysfunction as a central actor in intellectual disability-related diseases: an overview of Down syndrome, autism, Fragile X and Rett syndrome. Neurosci Biobehav Rev. 2014; 46:202–217. https://doi.org/10.1016/j.neubiorev.2014.01.012 PMID: 24548794

66. Valenti D, De Rasmo D, Signorile A, Rossi L, de Bari L, Scala I, et al. Epigallocatechin-3-gallate prevents oxidative phosphorylation deficit and promotes mitochondrial biogenesis in human cells from subjects with Down’s syndrome. Biochim Biophys Acta. 2013; 1832:542–552. https://doi.org/10.1016/j.bbadis.2012.12.011 PMID: 23291000

67. Wagatsuma A, Kotake N, Mabuchi K, Yamada S. Expression of nuclear-encoded genes involved in mitochondrial biogenesis and dynamics in experimentally denervated muscle. J Physiol Biochem. 2011; 67:359–370. https://doi.org/10.1083/jb.201003006 PMID: 21394548

68. Austin S and St-Pierre J. PGC1α and mitochondrial metabolism emerging concepts and relevance in ageing and neurodegenerative disorders. J Cell Sci. 2012; 125:4963–4971. https://doi.org/10.1242/jcs.113663 PMID: 23277535

69. Ye Q, Ye L, Xu X, Huang B, Zhang X, Zhu Y, et al. Epigallocatechin-3-gallate suppresses 1-methyl-4-phenylpyridine-induced oxidative stress in PC12 cells via the SIRT1/PGC-1α signaling pathway. BMC Complement Altern Med. 2012; 12: 82. https://doi.org/10.1186/1472-6882-12-82 PMID: 22742579

70. Zhang Y, Chen C, Jiang Y, Wang S, Wu X, and Wang K. PPARγ coactivator-1α (PGC-1α) protects neuroblastoma cells against amyloid-beta (Aβ) induced cell death and neuroinflammation via NF-κB pathway. BMC Neurosci. 2017; 18: 69. https://doi.org/10.1186/s12868-017-0387-7 PMID: 28946859
71. Collier JB, Whitaker RM, Eblen ST, Schnellmann RG. Rapid Renal Regulation of Peroxisome Proliferator-activated Receptor γ Coactivator-1α by Extracellular Signal-Regulated Kinase 1/2 in Physiological and Pathological Conditions. J Biol Chem. 2016; 291: 26850–26859. https://doi.org/10.1074/jbc.M116.754762 PMID: 27875304

72. Song C, Zhao J, Fu B, Li D, Mao T, Peng W, et al. Melatonin-mediated upregulation of Sirt3 attenuates sodium fluoride-induced hepatotoxicity by activating the MT1-PI3K/AKT-PGC-1α signaling pathway. Free Radic Biol Med. 2017; 112:616–630. https://doi.org/10.1016/j.freeradbiomed.2017.09.005 PMID: 28912098

73. Wang Z, Ye Z, Huang G, Wang N, Wang E, and Guo Q. Sevoflurane Post-conditioning Enhanced Hippocampal Neuron Resistance to Global Cerebral Ischemia Induced by Cardiac Arrest in Rats through PI3K/Akt Survival Pathway. Front Cell Neurosci. 2016; 10: 271. https://doi.org/10.3389/fncel.2016.00271 PMID: 27965539

74. Kang H, Khang R, Ham S, Jeong GR, Kim H, Jo M, et al. Activation of the ATF2/CREB-PGC-1α pathway by metformin leads to dopaminergic neuroprotection. Oncotarget. 2017; 8:48603–48618. https://doi.org/10.18632/oncotarget.18122 PMID: 28611284

75. Yu L, Gong B, Duan W, Fan C, Zhang J, Li Z, et al. Melatonin ameliorates myocardial ischemia/reperfusion injury in type 1 diabetic rats by preserving mitochondrial function: role of AMPK-PGC-1α-SIRT3 signaling. Sci Rep. 2017; 7: 41337. https://doi.org/10.1038/srep41337 PMID: 28120943